Antimicrobial cationic peptides

Details Antimicrobial cationic peptides Antimicrobial cationic peptides

2000-06-13

2002-10-15

Carlson, Karen Cochrane (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C514S013800, C530S324000, C530S325000, C530S326000, C530S334000, C435S069100

Reexamination Certificate

active

06465429

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to antimicrobial peptides and specifically to a new class of antimicrobial cationic peptides referred to as bactolysins.
2. Description of related Art
In 1981, the self-promoted uptake hypothesis was first proposed to explain the mechanism of action of polycationic antibiotics in
Pseudomonas aeruginosa
. According to this hypothesis, polycations interact with sites on the outer membranes of Gram-negative bacteria at which divalent cations cross-bridge adjacent lipopolysaccharide molecules. Due to their higher affinity for these sites, polycations displace the divalent cations and, since the polycations are bulkier than the divalent cations, cause structural perturbations in the outer membrane. These perturbations result in increased outer membrane permeability to compounds such as the &bgr;-lactam antibiotic nitrocefin, the eukaryotic non-specific defense protein lysozyme and to hydrophobic substances. By analogy, molecules accessing this pathway are proposed to promote their own uptake.
It has been clearly demonstrated that the outer membranes of Gram-negative bacteria are semipermeable molecular “sieves” which restrict access of antibiotics and host defense molecules to their targets within the bacterial cell. Thus, cations and polycations which access the self-promoted uptake system are, by virtue of their ability to interact with and break down the outer membrane permeability barrier, capable of increasing the susceptibility of Gram-negative pathogenic bacteria to antibiotics and host defense molecules. Hancock and Wong demonstrated that a broad range of such compounds could overcome the permeability barrier and coined the name “permeabilizers” to describe them (Hancock and Wong,
Antimicrob. Agents Chemother
., 26:48, 1984). While self-promoted uptake and permeabilizers were first described for P. aeruginosa, they have now been described for a variety of Gram-negative bacteria.
Over the past decade, non-specific defense molecules have been described in many animals, including insects and humans. One subset of these molecules have in common the following features: (a) they are small peptides, usually 15-35 amino acids in length, (b) they contain 4 or more positively charged amino acid residues, either lysines or arginines, and (c) they are found in high abundance in the organisms from which they derive. Several of these molecules have been isolated, amino acid sequenced and described in the patent literature (e.g., cecropins: WO 8900199, WO 8805826, WO 8604356, WO 8805826; defensins: EP 193351, EP 85250, EP 162161, U.S. Pat. No. 4,659,692, WO 8911291). However, only limited amounts of these peptides can be isolated from the host species. For example, Sawyer, et al., (
Infect. Immun
. 56:693, 1988) isolated 100-200 mg of rabbit neutrophil defensins 1 and 2 from 10
9
primed peritoneal neutrophils or lipopolysaccharide-elicited alveolar macrophages (i.e., the numbers present in a whole animal).
The gene for human defensin has been cloned and sequenced, but no successful expression has been demonstrated, as yet. Furthermore, production of these peptides using peptide synthesis technology produces peptides in limited amounts and is expensive when scaled up or when many variant peptides must be produced. Also, structural analysis is difficult without specific incorporation of
15
N and
13
C tagged amino acids which is prohibitively expensive using amino acid synthesis technology.
There is a need to develop polypeptides having a broad range of potent antimicrobial activity against a plurality of microorganisms, including gram negative bacteria, gram positive bacteria, fungi, protozoa, viruses and the like.
SUMMARY OF THE INVENTION
The present invention provides a novel class of cationic peptides, referred to as bactolysins, which have antimicrobial activity. Two representative peptides are provided and include MBI 29, KWKSFIKKLTTAVKKVLTTGLPALIS (SEQ ID NO:1) and MBI 26, KWKSFIKKLTSAAKKVVTTAKPLISS (SEQ ID NO:2), analogs, derivatives and conservative variations thereof.
The invention also provides a method of inhibiting the growth of bacteria comprising contacting the bacteria with an inhibiting effective amount of a peptide having an amino acid sequence of MBI 29 (SEQ ID NO:1) or MBI 26 (SEQ ID NO:2) alone, or in combination with an antibiotic. Classes of antibiotics which can be used for synergistic therapy with the peptides of the invention include aminoglycoside, penicillin, cephalosporine, fluoroquinolone, carbepenem, tetracycline and macrolide.
In another embodiment, the invention provides a method of inhibiting an endotoxemia or sepsis associated disorder in a subject having or at risk of having such a disorder, comprising administering to the subject a therapeutically effective amount of a peptide of the invention.


REFERENCES:
patent: 4810777 (1989-03-01), Zasloff
patent: 4822608 (1989-04-01), Benton et al.
patent: 5017486 (1991-05-01), Sawai et al.
patent: 5028530 (1991-07-01), Lai et al.
patent: 5073542 (1991-12-01), Zasloff
patent: 5166321 (1992-11-01), Lai et al.
patent: 5202420 (1993-04-01), Zasloff et al.
patent: 5206154 (1993-04-01), Lai et al.
patent: 5208220 (1993-05-01), Berkowitz
patent: 5217956 (1993-06-01), Zasloff et al.
patent: 5235038 (1993-08-01), Blondelle et al.
patent: 5254535 (1993-10-01), Zasloff et al.
patent: 5344765 (1994-09-01), Lai et al.
patent: 5357044 (1994-10-01), Lai et al.
patent: 5484885 (1996-01-01), Pereira et al.
patent: 5585353 (1996-12-01), Merrifield et al.
patent: 5593866 (1997-01-01), Hancock et al.
patent: 5877274 (1999-03-01), Hancock et al.
patent: 6057291 (2000-05-01), Hancock et al.
patent: 2040510 (1991-10-01), None
patent: 8911290 (1989-11-01), None
patent: 9004407 (1990-05-01), None
patent: 9004408 (1990-05-01), None
patent: 9008552 (1990-08-01), None
patent: 9012866 (1990-11-01), None
patent: 9108758 (1991-06-01), None
patent: 9112015 (1991-08-01), None
patent: 9116918 (1991-11-01), None
patent: 9117760 (1991-11-01), None
patent: 9217195 (1992-10-01), None
patent: 9217197 (1992-10-01), None
patent: 9222317 (1992-12-01), None
patent: 9301723 (1993-02-01), None
patent: 9305802 (1993-04-01), None
patent: 9311783 (1993-06-01), None
patent: 9324138 (1993-12-01), None
patent: 9404688 (1994-03-01), None
patent: WO 96/28559 (1996-09-01), None
patent: WO 96/38473 (1996-12-01), None
Kreil (1973) FEBS Lett. 33:241-244.
K.L. Piers et al., “The Interaction of a recombinant cecropin/melittin hybrid peptide with the outer membrane ofPseudomonas aeruginosa”, Molecular Microbiology,vol. 12, No. 6, 1994, pp. 951-958.
J.W. Larrick, et al., “A Novel Granulocyte-Derived Peptide with Lipopolysaccharide-Neutralizing Activity”,Journal of Immunological Methods,vol. 152, New York, US, pp. 231-240.
Hirata et al., “Structure and Functions of Endotoxin-Binding Peptides Derived from CAP18”,Bacterial Endotoxins:Lipopolysaccharides from Genes to Therapy,pp. 317-326, 1995.
Sawyer, J.G., et al., “Interaction of Macrophage Cationic Proteins with the Outer Membrane ofPseudomonas aeruginosa”, Infection and Immunity,Mar. 1988, vol. 56, No. 3, pp. 693-698.
Wade, D., et al, “Antibacterial peptides designed as analogs or hybrids of cecropins and melittin”,Int. J. Peptide Res.,40(5), 1992, pp. 429-436.
Kohn, F.R., et al., “Protective Effect of a Recombinant Amino-Terminal Fragment of Bactericida/Permeability-Increasing Protein in Experimental Endotoxemia”,J. Infect. Dis.,Nov. 1993: 168(5), pp. 1307-1310.
Larrick, J.W., et al., “A Novel Granulocyte-Derived Peptide with Lipopolysaccharide-Neutralizing Activity”,J. Immunol.,152(1):231-240.
Coyne, C.P., et al., “Inhibition of lipopolysaccharide-induced macrophage tumor necrosis factor-&agr; synthesis by polymyxin B sulfate”,Am. J. Vet. Res.,vol. 54, No. 2, Feb. 1993, pp. 305-314.
Andersons, D., et al., “Biologically active and amidated cecropin produced in a baculovirus expression system from a fusion construct containing the antibody-binding part of protein A”,Biochem J.,(1991) 280, pp. 219-224.
K.L. Piers et al., “Recombinant

Affiliated with

Also associated with

Rating

Antimicrobial cationic peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antimicrobial cationic peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antimicrobial cationic peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2995035